These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 16753346

  • 1. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons.
    Aartsma-Rus A, Kaman WE, Weij R, den Dunnen JT, van Ommen GJ, van Deutekom JC.
    Mol Ther; 2006 Sep; 14(3):401-7. PubMed ID: 16753346
    [Abstract] [Full Text] [Related]

  • 2. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JC.
    BMC Med Genet; 2007 Jul 05; 8():43. PubMed ID: 17612397
    [Abstract] [Full Text] [Related]

  • 3. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.
    Aartsma-Rus A, Kaman WE, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC.
    Gene Ther; 2004 Sep 05; 11(18):1391-8. PubMed ID: 15229633
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
    Errington SJ, Mann CJ, Fletcher S, Wilton SD.
    J Gene Med; 2003 Jun 05; 5(6):518-27. PubMed ID: 12797117
    [Abstract] [Full Text] [Related]

  • 10. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
    Gurvich OL, Tuohy TM, Howard MT, Finkel RS, Medne L, Anderson CB, Weiss RB, Wilton SD, Flanigan KM.
    Ann Neurol; 2008 Jan 05; 63(1):81-9. PubMed ID: 18059005
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides.
    Aartsma-Rus A, Janson AA, Heemskerk JA, De Winter CL, Van Ommen GJ, Van Deutekom JC.
    Ann N Y Acad Sci; 2006 Oct 05; 1082():74-6. PubMed ID: 17145928
    [Abstract] [Full Text] [Related]

  • 12. Optimizing RNA/ENA chimeric antisense oligonucleotides using in vitro splicing.
    Takeshima Y, Yagi M, Matsuo M.
    Methods Mol Biol; 2012 Oct 05; 867():131-41. PubMed ID: 22454059
    [Abstract] [Full Text] [Related]

  • 13. Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle.
    Takeshima Y, Yagi M, Wada H, Matsuo M.
    Brain Dev; 2005 Oct 05; 27(7):488-93. PubMed ID: 16198206
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
    Graham IR, Hill VJ, Manoharan M, Inamati GB, Dickson G.
    J Gene Med; 2004 Oct 05; 6(10):1149-58. PubMed ID: 15386737
    [Abstract] [Full Text] [Related]

  • 17. Induced dystrophin exon skipping in human muscle explants.
    McClorey G, Fall AM, Moulton HM, Iversen PL, Rasko JE, Ryan M, Fletcher S, Wilton SD.
    Neuromuscul Disord; 2006 Oct 05; 16(9-10):583-90. PubMed ID: 16919955
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.